Vogensen, VBAnthony, RMKerstjens, HAMTiberi, Sde Steenwinkel, JEMAkkerman, OW2025-03-312025-03-3120223537827110.1016/j.cmi.2022.03.033https://rivm.openrepository.com/handle/10029/654248The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazidArticleClin Microbiol Infect 2022; 28(8):1047-10492025-03-31